CO-DIAGNOSTICS INC
CODXNASDAQTrading Snapshot
- Day Range
- $1.06 – $1.08
- 52-Week Range
- $0.91 – $46.50
- Volume
- $2.75B
- Avg Volume
- $2.24B
- Shares Outstanding
- 1.1M
- Next Earnings
- Dec 7, 2026
Fundamentals Snapshot
- Annual Revenue
- $622,489
- Last Q Revenue
- $166,131
- P/E Ratio
- -0.0
- P/S Ratio
- 1.7x
- EPS (TTM)
- $-10.92
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +20.7%
Why Investors Own CODX
- ✓High-growth profile — revenue up +42.9% YoY with expanding US Equity exposure.
- ✓Healthy economics — 65% gross margin and 22% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
CO-DIAGNOSTICS INC
CODX
StockOtter · stockotter.spaceAbout CO-DIAGNOSTICS INC
Co-Diagnostics, Inc. operates as a molecular diagnostics company that develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. The company offers Co-Dx PCR platform, a polymerase chain reaction testing to patients in point-of-care and at-home setting. It also provides PCR diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, human papillomavirus, malaria, chikungunya, dengue, and the zika virus. In addition, the company offers three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications; tests that identify genetic traits in plant and animal genomes; and portable diagnostic device designed to bring PCR to patients in point-of-care and at-home settings. The company was incorporated in 2013 and is based in Salt Lake City, Utah.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Ratings
ⓘLatest News & Updates
Head to Head Review: Halozyme Therapeutics (NASDAQ:HALO) & Co-Diagnostics (NASDAQ:CODX)
Halozyme Therapeutics (NASDAQ: HALO - Get Free Report) and Co-Diagnostics (NASDAQ: CODX - Get Free Report) are both healthcare companies, but which is the better business? We will contrast the two companies based on the
Co-Diagnostics to Participate in Global Health Events During UN General Assembly Week
Events Bring Together Global Health Leaders to Examine Tuberculosis and Preparedness for the Next Respiratory Pandemic SALT LAKE CITY, Sept. 23, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the C
Co-Diagnostics to Participate in Global Health Roundtable on Ebola and Outbreak Innovation
Roundtable discussion, taking place in New York City, will examine the ongoing Ebola outbreak and technologies needed to strengthen future outbreak response. Co-Dx will join officials from the U.S. Department of State's
Co-Diagnostics to Participate in Joint WHO/Unitaid/UNAIDS Annual Consultation Meeting on September 17-18, 2026
SALT LAKE CITY, Sept. 17, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic
Co-Diagnostics, Inc. (CODX) Shareholder/Analyst Call Transcript
Co-Diagnostics, Inc. (CODX) Shareholder/Analyst Call Transcript
Co-Diagnostics and ReadyGo Collaborate to Evaluate Blood-Based Molecular Testing at the Point of Need, Starting with Ebola
Blood-based testing could open new markets for the Co-Dx® PCR platform, including HIV and hepatitis B and C Co-Diagnostics and ReadyGo target decentralized Ebola detection as the first application of their collaboration